Real-time Quotes | Nasdaq Last Sale

After Hours: 1.460 -0.01 -0.68% 17:28 11/23 EST
Corp Actions
Medigus, 180 Life Sciences leads healthcare gainers; Bellerophon Therapeutics, BioLineRx among major losers
Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio (IBIO) -10%, OptiNose (OPTN) -10%.
Seekingalpha · 6h ago
Vaccine access and distribution a big topic at G20
At this weekend's summit in Riyadh, G20 leaders pledged to ensure fair distribution of COVID-19 vaccines, drugs and tests around the world so that poorer countries were not left out
Seekingalpha · 1d ago
Stay Away From iBio, Which Constantly Issues Shares to Survive
I’ve been waiting to write about iBio (NYSEAMERICAN:IBIO) in order to see their earnings report and give readers a better handle on the latest IBIO news. As usual, there is nothing worth investing in with this company. Most investors should stay far away from IBIO stock. Source: Shutterstock In fact, the only thing of note that happened this quarter is that the company was somehow able to issue even more shares for about $27 million. This was reported in an obscure footnote in the company’s recent 10-Q filing (Page 25). The company’s cash pile is now up to $77.5 million. That’s great. But here is the issue: IBIO stock has a market capitalization over 3 times this amount at $295 million.InvestorPlace - Stock Market News, Stock Advice & Trading Tips IBIO News: Burning Cash The biggest headline for iBio right now is this: the company is burning cash for the foreseeable future. So far this year, the company’s cash burn has been over $13.6 billion (Page 6). This figure was taken from its cash flow statement, which was not on the earnings release but in its 10-Q filing. 8 Tech Stocks That Could Benefit from a Biden Presidency So, in order to finance this tremendous outflow of capital, the company has had to issue shares. On a net basis, it has sold $36 million in IBIO stock so far this fiscal year ending in June 2021. I would suspect that as its losses continue, you will continue to see further dilution. For example, last year ending June 30, 2020, iBio burnt through $14.5 million. Therefore — so far during its first fiscal quarter ending Sept. 30 — the company has already burnt through the equivalent of over 93% of its entire last fiscal year. At this pace, it will burn through $54.4 million for the rest of its fiscal year ending in June 2021. That would eat up a huge portion of the $77.5 million it has in the bank. Given this record, don’t expect to see the stock move up as its cash drains faster. In fact, you can already see what has happened. On Page 8 of its 10-Q filing, the company said that it has issued $68.97 million for 30.2 million shares under its Lincoln Park equity facility. I wrote about this earlier. This is essentially an equity line of credit. The bottom line is that the average price for the equity sales is $2.28 per share — $68.97 million divided by 30.2 million shares. But the problem is IBIO stock is now trading at around $1.60 as of Nov. 20. That is a miserable track record, for both the new and existing shareholders. What to Do with Shares in IBIO I have been consistently negative on IBIO stock in my past three articles on the company. Other than a short-lived spike in July to over $7 per share, the stock has generally traded between the high side of $1 to the low side of $2. This is likely to continue. One reason for this is that iBio’s proposed Covid-19 vaccine candidate has not really taken off. The company is still stuck in early pre-trial actions. And now it seems that other companies have already beaten iBio to the punch in this space. Moderna (NASDAQ:MRNA) announced on Nov. 16 that its novel coronavirus vaccine candidate is 94.5% effective. Along with Pfizer’s (NYSE:PFE) recent report of 95% effectiveness in its vaccine, this essentially puts iBio’s chances to bed. Both companies will likely receive approval from the FDA soon in order to begin nationwide distribution. Moreover, iBio has yet to produce any kind of significant revenue from any of its vaccine or plant-based products. I don’t see that turning around anytime in the near future. By the way, my view on the company seems to be away from the consensus. For example, the analyst report surveyed by has the stock at an average price target of $2. However, there is only one analyst with this price and they recently lowered their price down from $3. Of course, though, one report is also not enough to make a real consensus. Therefore, I stand by my recommendation. Stay away from IBIO stock for the time being. It’s better for investors to wait until there are more reasonable prospects for the company before investing in this money pit. On the date of publication, Mark Hake did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. Mark Hake runs the Total Yield Value Guide which you can review here. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Stay Away From iBio, Which Constantly Issues Shares to Survive appeared first on InvestorPlace.
InvestorPlace · 3d ago
KNDI, RIOT, IBIO and GDRX among midday movers
Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Sequential Brands (SQBG)
Seekingalpha · 6d ago
Lexicon Pharmaceuticals, Zomedica Pharmaceuticals leads healthcare gainers; Brainstorm Cell Therapeutics, GoodRx Holdings among losers
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) -19%, iBio (IBIO) -18%, Co-Diagnostics (CODX) -17%, Alterity Therapeutics (ATHE) -16%.
Seekingalpha · 6d ago
CVS Health, Walgreens Boots Alliance among major healthcare premarket losers' pack
Brainstorm Cell Therapeutics (BCLI) -69% after announcing topline results from Phase 3 trial evaluating NurOwn.Alterity Therapeutics (ATHE) -24%.iBio (IBIO) -20% on FQ1 earnings release.The Alkaline Water Company (WTER) -17% on FQ2 earnings release.GoodRx Holdings (GDRX) -18% tumble after
Seekingalpha · 6d ago
Up 600% Year-to-Date, Sell iBio Stock While Its Still Flying High
It’s been an incredible comeback year for iBio (NYSEAMERICAN:IBIO). Up until 2020, IBIO stock had a long and unfortunate run as a publicly traded investment. Shares dropped from a peak of $55 each in 2011 to as low as 5 cents last year. However, for the fledgling biotech and vaccine company, the novel coronavirus gave it a new lease on life. Here’s the latest in iBio news. Source: Maksim Shmeljov / Shares roared from that 5-cent low to as high as $7 this year. That came as iBio reported that it had two pre-clinical candidates for a potential Covid-19 vaccine. Like many of the coronavirus vaccine competitors, however, iBio never managed to transform that clinical promise into much in the way of tangible results. As a result, IBIO stock has slid from that $7 peak back to $2. And shares are set to head much lower going forward now that Pfizer (NYSE:PFE) has a working vaccine and Moderna (NASDAQ:MRNA) is also waiting in the wings in case anything goes wrong with the Pfizer one.InvestorPlace - Stock Market News, Stock Advice & Trading Tips 7 Retail Stocks That Will Benefit From 2020’s Holiday Shopping Season The search for a successful coronavirus vaccine has now just about concluded, and that leaves very little left in the tank for iBio as far as future prospects go. Lots Of Developments, But Minimal Revenues For iBio’s most recent quarterly results, in the press release, the company started off by discussing the 16 different new business initiatives iBio has launched over the past year. This includes a full spectrum of things ranging from bioink for 3D-printing organs to something about deploying blockchain to track pharmaceutical manufacturing. There’s a bunch of stuff that sounds futuristic and exciting. However, as is almost always the case with iBio, there’s little evidence of any of this turning into a commercial business in the foreseeable future. For the fiscal year that ended June 30, iBio produced just $1.6 million in revenues. That’s not a lot. In fact, it’s actually a decline from the previous year, when iBio generated $2 million in revenues. Despite all the furor over the potential coronavirus vaccine, iBio’s business outright shrunk. IBIO News: Is This Really Worth $315 Million? As of this writing, iBio has a market capitalization of $315 million. That’s the price traders are willing to pay for this company that has less than $2 million per year in revenues and loses large sums of money. Looking back, over the past year, iBio lost $16 million while producing just $1.6 million in revenue. That’s not a good ratio. The one place you can give iBio credit is its balance sheet. Management took advantage of the spike in IBIO’s stock price and issued shares. In fact, the firm did so repeatedly, first selling stock to institutional investors. Then, iBio launched an at-the-money (ATM) offering to issue stock to the general public as well. In doing all this fundraising, iBio has lifted its cash position to $83 million, which is way up from the $4 million that it had in 2019. However, of course, that money didn’t come without strings. In fact, incredibly enough, iBio’s share count has gone up seven-fold — from 20 million to 140 million — over the past year. Thus, even in the event that iBio manages to start generating meaningful revenues, the stock price still might not do much given just how much dilution has already occurred. In any case, the cash holding will give IBIO stock a floor. But that’s at a much lower level than the current share price. $83 million of cash does not come close to backing up a $315 million market cap on a firm that historically loses tons of money and has never generated significant amounts of revenue. IBIO Stock Verdict The fact of the matter is that the Pfizer vaccine now appears set to start generating commercial revenues. And even if something unexpected happens to the Pfizer vaccine, Moderna is on deck with another strong candidate of its own. Neither of those rely on plant-based technologies to work. In fact, there’s scant historical examples of successful revenue-generating vaccines based on the sort of technology iBio is using. That’s not to say iBio’s product won’t necessarily work. But the time for such an effort has come and gone. A vaccine in early clinical stages of trials based on an unproven platform simply doesn’t have much value in a world where Pfizer is already launching its effective vaccine momentarily. Recall that iBio had projects related to Ebola, another catastrophic infectious disease. But iBio was unable to convert that effort into meaningful profits either. In fact, iBio paid damages in a lawsuit relating to allegedly false and misleading claims it made about an experimental Ebola drug. In any case, iBio has not had a reputation for speedy product development in its decade as a public company, which in large part helps explain why the company has struggled. Whether or not iBio’s Covid-19 vaccine ultimately is effective, it will be too little too late. IBIO stock traded for 5 cents per share within the past year. Now that its Covid-19 ambitions are fading, what’s the reason to keep holding the stock way up at $2 per share? Bottom line: the iBio news is not promising. On the date of publication, Ian Bezek did not have (either directly or indirectly) any positions in the securities mentioned in this article. Ian Bezek has written more than 1,000 articles for and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. You can reach him on Twitter at @irbezek. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Up 600% Year-to-Date, Sell iBio Stock While It’s Still Flying High appeared first on InvestorPlace.
InvestorPlace · 11/13 15:48
Second tier COVID-19 vaccine developers under pressure on positive Pfizer/BioNTech data
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure
Seekingalpha · 11/09 15:14
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBIO. Analyze the recent business situations of IBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IBIO stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
Institutional Holdings
Institutions: 16
Institutional Holdings: 332.24K
% Owned: 0.18%
Shares Outstanding: 182.11M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Pharmaceuticals & Medical Research
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Isett
Robert Erwin
Chief Accounting Officer
John Delta
Linda Armstrong
Robert Kay
Alexandra Kropotova
Gary Sender
Independent Director
Glenn Chang
Independent Director
Seymour Flug
Independent Director
James Hill
Independent Director
John McKey
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IBIO
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
Hot Stocks

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.